Trial Outcomes & Findings for Safety Study of PLX4032 in Patients With Solid Tumors (NCT NCT00405587)

NCT ID: NCT00405587

Last Updated: 2017-08-22

Results Overview

AUC (0-8 hour) was defined as the area under the plasma concentration-time curve from time equals zero (0) to 8 hours post-dose. AUC (0-24 hour) was defined as the area under the plasma concentration-time curve from time equals 0 to 24 hours post-dose. AUC (0-8 hour) and AUC (0-24 hour) were computed using the linear trapezoidal rule.

• Recruitment status: COMPLETED
• Study phase: PHASE1
• Target enrollment: 109 participants
• Primary outcome timeframe: Pre-morning dose and at 0.5, 1, 2, 4, and 8, and 24 hours post-morning dose
• Results posted on: 2017-08-22

Participant Flow

Enrollment to "Dose Escalation: Original Formulation" was halted based on bioavailability results and the drug was reformulated as microprecipitated bulk powder (MBP) and then the enrollment was resumed in "Dose Escalation: MBP Formulation" arm

Participant milestones

Measure	Dose Escalation: Original Formulation Cohorts of 3 to 6 participants received RO5185426 capsules in original (crystalline) formulation at a starting dose of 200 mg BID for 4 weeks. After Day 15 pharmacokinetic assessment and adequate safety and tolerability was shown, next cohort of 3 to 6 participants received 50 % to 100% increased dose of RO5185426 original formulation for 4 weeks. Dose escalation was continued up to 1600 mg BID dose level.	Dose Escalation: MBP Formulation Cohorts of 3 to 6 participants received RO5185426 capsules/tablets in MBP formulation at a starting dose of 160 mg BID for 4 weeks. After Day 15 pharmacokinetic assessment and adequate safety and tolerability was shown, next cohort of 3 to 6 participants received 50 % to 100% increased dose of RO5185426 MBP formulation for 4 weeks. Dose escalation was continued up to unacceptable toxicity or disease progression occurred.	Extension: BRAFV600E- Positive Melanoma Participants with melanoma tumors that carried the V600E mutation of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) received RO5185426 capsules/tablets in MBP formulation at a dose of 960 mg BID until disease progression, death, or withdrawal from the study.	Extension: BRAFV600E- Positive CRC Participants with CRC that carried the V600E mutation of BRAF received RO5185426 capsules/tablets in MBP formulation at a dose of 960 mg BID until disease progression, death, or withdrawal from the study.
Overall Study STARTED	26	30	32	21
Overall Study COMPLETED	0	2	10	1
Overall Study NOT COMPLETED	26	28	22	20

Reasons for withdrawal

Measure	Dose Escalation: Original Formulation Cohorts of 3 to 6 participants received RO5185426 capsules in original (crystalline) formulation at a starting dose of 200 mg BID for 4 weeks. After Day 15 pharmacokinetic assessment and adequate safety and tolerability was shown, next cohort of 3 to 6 participants received 50 % to 100% increased dose of RO5185426 original formulation for 4 weeks. Dose escalation was continued up to 1600 mg BID dose level.	Dose Escalation: MBP Formulation Cohorts of 3 to 6 participants received RO5185426 capsules/tablets in MBP formulation at a starting dose of 160 mg BID for 4 weeks. After Day 15 pharmacokinetic assessment and adequate safety and tolerability was shown, next cohort of 3 to 6 participants received 50 % to 100% increased dose of RO5185426 MBP formulation for 4 weeks. Dose escalation was continued up to unacceptable toxicity or disease progression occurred.	Extension: BRAFV600E- Positive Melanoma Participants with melanoma tumors that carried the V600E mutation of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) received RO5185426 capsules/tablets in MBP formulation at a dose of 960 mg BID until disease progression, death, or withdrawal from the study.	Extension: BRAFV600E- Positive CRC Participants with CRC that carried the V600E mutation of BRAF received RO5185426 capsules/tablets in MBP formulation at a dose of 960 mg BID until disease progression, death, or withdrawal from the study.
Overall Study Death	0	0	0	1
Overall Study Disease Progression	22	23	21	17
Overall Study Physician Decision	3	2	0	0
Overall Study Adverse Event	1	0	0	0
Overall Study Lost to Follow-up	0	1	1	0
Overall Study Radiation induced necrosis	0	1	0	0
Overall Study Withdrawal by Subject	0	0	0	2
Overall Study Participant not dosed	0	1	0	0

Baseline Characteristics

Safety Study of PLX4032 in Patients With Solid Tumors

Baseline characteristics by cohort

Measure	Dose Escalation: Original Formulation n=26 Participants Cohorts of 3 to 6 participants received RO5185426 capsules in original (crystalline) formulation at a starting dose of 200 mg BID for 4 weeks. After Day 15 pharmacokinetic assessment and adequate safety and tolerability was shown, next cohort of 3 to 6 participants received 50 % to 100% increased dose of RO5185426 original formulation for 4 weeks. Dose escalation was continued up to 1600 mg BID dose level.	Dose Escalation: MBP Formulation n=30 Participants Cohorts of 3 to 6 participants received RO5185426 capsules/tablets in MBP formulation at a starting dose of 160 mg BID for 4 weeks. After Day 15 pharmacokinetic assessment and adequate safety and tolerability was shown, next cohort of 3 to 6 participants received 50 % to 100% increased dose of RO5185426 MBP formulation for 4 weeks. Dose escalation was continued up to unacceptable toxicity or disease progression occurred.	Extension: BRAFV600E- Positive Melanoma n=32 Participants Participants with melanoma tumors that carried the V600E mutation of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) received RO5185426 capsules/tablets in MBP formulation at a dose of 960 mg BID until disease progression, death, or withdrawal from the study.	Extension: BRAFV600E- Positive CRC n=21 Participants Participants with CRC that carried the V600E mutation of BRAF received RO5185426 capsules/tablets in MBP formulation at a dose of 960 mg BID until disease progression, death, or withdrawal from the study.	Total n=109 Participants Total of all reporting groups
Age, Continuous	65.5 years STANDARD_DEVIATION 13.75 • n=5 Participants	58.0 years STANDARD_DEVIATION 14.77 • n=7 Participants	50.4 years STANDARD_DEVIATION 13.54 • n=5 Participants	63.6 years STANDARD_DEVIATION 14.86 • n=4 Participants	58.6 years STANDARD_DEVIATION 15.24 • n=21 Participants
Sex: Female, Male Female	11 Participants n=5 Participants	11 Participants n=7 Participants	14 Participants n=5 Participants	10 Participants n=4 Participants	46 Participants n=21 Participants
Sex: Female, Male Male	15 Participants n=5 Participants	19 Participants n=7 Participants	18 Participants n=5 Participants	11 Participants n=4 Participants	63 Participants n=21 Participants

PRIMARY outcome

Timeframe: Pre-morning dose and at 0.5, 1, 2, 4, and 8, and 24 hours post-morning dose

Population: Pharmacokinetic (PK) Population: Participants who received all RO5185426 doses without dose reduction up to and including Day 15 and provided at least PK assessments up to and including 8 to 10 hours after first dose on Day 15. Number of participants analyzed=participants evaluable for this outcome; n=participants evaluable for specified category.

AUC (0-8 hour) was defined as the area under the plasma concentration-time curve from time equals zero (0) to 8 hours post-dose. AUC (0-24 hour) was defined as the area under the plasma concentration-time curve from time equals 0 to 24 hours post-dose. AUC (0-8 hour) and AUC (0-24 hour) were computed using the linear trapezoidal rule.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=6 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
Area Under the Plasma Concentration-Time Curve (AUC) of RO5185426 on Day 1 - Dose Escalation: Original Formulation AUC (0-8 hour) (n= 6, 4, 4, 4)	2.02 ug*hr/mL Standard Deviation 1.03	3.28 ug*hr/mL Standard Deviation 1.66	4.47 ug*hr/mL Standard Deviation 0.61	4.23 ug*hr/mL Standard Deviation 2.0	—	—
Area Under the Plasma Concentration-Time Curve (AUC) of RO5185426 on Day 1 - Dose Escalation: Original Formulation AUC (0-24 hour) (n= 6, 4, 4, 4)	8.43 ug*hr/mL Standard Deviation 4.84	14.86 ug*hr/mL Standard Deviation 7.89	21.66 ug*hr/mL Standard Deviation 10.59	22.34 ug*hr/mL Standard Deviation 10.59	—	—

PRIMARY outcome

Timeframe: Pre-morning dose and at 0.5, 1, 2, 4, and 8, and 24 hours post-morning dose

Population: PK Population: Participants who received all RO5185426 doses without dose reduction up to and including Day 15 and provided at least PK assessments up to and including 8 to 10 hours after first dose on Day 15. Number of participants analyzed=participants evaluable for this outcome; n=participants evaluable for specified category.

AUC (0-8 hour) was defined as the area under the plasma concentration-time curve from time equals 0 to 8 hours post-dose. AUC (0-24 hour) was defined as the area under the plasma concentration-time curve from time equals 0 to 24 hours post-dose. AUC (0-8 hour) and AUC (0-24 hour) were computed using the linear trapezoidal rule.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=6 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg n=3 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg n=3 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
Area Under the Plasma Concentration-Time Curve (AUC) of RO5185426 on Day 15 - Dose Escalation: Original Formulation AUC (0-8 hour) (n=6, 3, 3, 4)	9.37 ug*hr/mL Standard Deviation 6.18	30.90 ug*hr/mL Standard Deviation 11.44	30.58 ug*hr/mL Standard Deviation 7.08	33.89 ug*hr/mL Standard Deviation 17.24	—	—
Area Under the Plasma Concentration-Time Curve (AUC) of RO5185426 on Day 15 - Dose Escalation: Original Formulation AUC (0-24 hour) (n= 2, 2, 3, 4)	46.28 ug*hr/mL Standard Deviation 10.47	105.10 ug*hr/mL Standard Deviation 65.41	91.01 ug*hr/mL Standard Deviation 26.86	101.13 ug*hr/mL Standard Deviation 48.40	—	—

PRIMARY outcome

Timeframe: Pre-morning dose and at 0.5, 1, 2, 4, and 8 hours post-morning dose on Day 1, pre-morning dose on Day 2 and Day 8

Population: PK Population: Participants who received all RO5185426 doses without dose reduction up to and including Day 15 and provided at least PK assessments up to and including 8 to 10 hours after first dose on Day 15. Number of participants analyzed=participants evaluable for this outcome.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=6 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg n=3 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
Peak Concentration (Cmax) of RO5185426 on Day 1 - Dose Escalation: Original Formulation	0.37 Micrograms per milliliter Standard Deviation 0.2	0.58 Micrograms per milliliter Standard Deviation 0.27	0.85 Micrograms per milliliter Standard Deviation 0.06	0.73 Micrograms per milliliter Standard Deviation 0.38	—	—

PRIMARY outcome

Timeframe: Pre-morning dose and at 0.5, 1, 2, 4, and 8 hours post-morning dose on Day 15, pre-morning dose on Day 16

Population: PK Population: Participants who received all RO5185426 doses without dose reduction up to and including Day 15 and provided at least PK assessments up to and including 8 to 10 hours after first dose on Day 15. Number of participants analyzed=participants evaluable for this outcome.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=6 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg n=3 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg n=3 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
Peak Concentration (Cmax) of RO5185426 on Day 15 - Dose Escalation: Original Formulation	1.34 Micrograms per milliliter Standard Deviation 0.81	4.57 Micrograms per milliliter Standard Deviation 2.07	5.41 Micrograms per milliliter Standard Deviation 2.26	5.34 Micrograms per milliliter Standard Deviation 3.04	—	—

PRIMARY outcome

Timeframe: Pre-morning dose, 0.5, 1, 2, 4, and 8 hour post-morning dose on Day 1, pre-morning dose on Day 2 and Day 8

Population: PK Population: Participants who received all RO5185426 doses without dose reduction up to and including Day 15 and provided at least PK assessments up to and including 8 to 10 hours after first dose on Day 15. Number of participants analyzed=participants evaluable for this outcome.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=6 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg n=3 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
Time to Peak Concentration (Tmax) of RO5185426 on Day 1 - Dose Escalation: Original Formulation	9.98 hours Interval 4.0 to 10.0	4 hours Interval 4.0 to 4.25	3.01 hours Interval 2.0 to 8.08	4 hours Interval 2.0 to 4.0	—	—

PRIMARY outcome

Timeframe: Pre-morning dose, 0.5, 1, 2, 4, and 8 hour post-morning dose on Day 15, pre-morning dose on Day 16

Population: PK Population: Participants who received all RO5185426 doses without dose reduction up to and including Day 15 and provided at least PK assessments up to and including 8 to 10 hours after first dose on Day 15. Number of participants analyzed=participants evaluable for this outcome.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=6 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg n=3 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg n=3 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
Time to Peak Concentration (Tmax) of RO5185426 on Day 15 - Dose Escalation: Original Formulation	0.02 hours Interval 0.0 to 2.0	0.5 hours Interval 0.0 to 10.0	0 hours Interval 0.0 to 2.0	3 hours Interval 0.0 to 10.0	—	—

PRIMARY outcome

Timeframe: Pre-morning dose and at 0.5, 1, 2, 4, and 8, and 24 hours post-morning dose

Population: Pharmacokinetic (PK) Population: Participants who received all RO5185426 doses without dose reduction up to and including Day 15 and provided at least PK assessments up to and including 8 to 10 hours after first dose on Day 15. Number of participants analyzed=participants evaluable for this outcome; n=participants evaluable for specified category.

AUC (0-8 hour) was defined as the area under the plasma concentration-time curve from time equals zero (0) to 8 hours post-dose. AUC (0-24 hour) was defined as the area under the plasma concentration-time curve from time equals 0 to 24 hours post-dose. AUC (0-8 hour) and AUC (0-24 hour) were computed using the linear trapezoidal rule.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=3 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg n=6 Participants Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg n=5 Participants Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
AUC of RO5185426 on Day 1 - Dose Escalation: MBP Formulation	5.98 ug*hr/mL Standard Deviation 3.31	15.85 ug*hr/mL Standard Deviation 1.53	14.95 ug*hr/mL Standard Deviation 4.99	39.09 ug*hr/mL Standard Deviation 35.82	39.48 ug*hr/mL Standard Deviation 19.58	44.94 ug*hr/mL Standard Deviation 20.88

PRIMARY outcome

Timeframe: Pre-morning dose and at 0.5, 1, 2, 4, and 8, and 24 hours post-morning dose

Population: Pharmacokinetic (PK) Population: Participants who received all RO5185426 doses without dose reduction up to and including Day 15 and provided at least PK assessments up to and including 8 to 10 hours after first dose on Day 15. Number of participants analyzed=participants evaluable for this outcome; n=participants evaluable for specified category.

AUC (0-8 hour) was defined as the area under the plasma concentration-time curve from time equals zero (0) to 8 hours post-dose. AUC (0-24 hour) was defined as the area under the plasma concentration-time curve from time equals 0 to 24 hours post-dose. AUC (0-8 hour) and AUC (0-24 hour) were computed using the linear trapezoidal rule.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg n=3 Participants Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg n=4 Participants Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
AUC of RO5185426 on Day 15 - Dose Escalation: MBP Formulation AUC (0-8 hour) (n= 4, 4, 4, 4, 3, 4)	33.91 mcg*hr/mL Standard Deviation 19.14	71.64 mcg*hr/mL Standard Deviation 30.09	114.50 mcg*hr/mL Standard Deviation 35.33	212.28 mcg*hr/mL Standard Deviation 123.24	229.96 mcg*hr/mL Standard Deviation 42.75	536.47 mcg*hr/mL Standard Deviation 137.18
AUC of RO5185426 on Day 15 - Dose Escalation: MBP Formulation AUC (0-24 hour) (n= 2, 3, 3, 3, 2, 3)	87.18 mcg*hr/mL Standard Deviation 88.78	228.97 mcg*hr/mL Standard Deviation 81.03	373.94 mcg*hr/mL Standard Deviation 94.51	622.21 mcg*hr/mL Standard Deviation 406.89	649.29 mcg*hr/mL Standard Deviation 200.95	1494.27 mcg*hr/mL Standard Deviation 367.68

PRIMARY outcome

Timeframe: Day 1 and Day 15: pre-morning dose and at 0.5, 1, 2, 4, and 8 hours post-morning dose

Population: Pharmacokinetic (PK) Population: Participants who received all RO5185426 doses without dose reduction up to and including Day 15 and provided at least PK assessments up to and including 8 to 10 hours after first dose on Day 15. Number of participants analyzed=participants evaluable for this outcome; n=participants evaluable for specified category.

Accumulation ratio is the ratio of AUC (0-8 hour) on Day 15 / AUC (0-8 hour) on Day 1.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=3 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg n=3 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg n=3 Participants Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg n=3 Participants Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
Mean RO5185426 Accumulation Ratios - Dose Escalation: MBP Formulation	4.75 ratio Standard Deviation 3.14	4.47 ratio Standard Deviation 1.57	8.66 ratio Standard Deviation 5.37	8.89 ratio Standard Deviation 6.03	10.11 ratio Standard Deviation 3.09	13.86 ratio Standard Deviation 4.68

PRIMARY outcome

Timeframe: Day 1 and Day 15: pre-morning dose and at 0.5, 1, 2, 4, and 8 hours post-morning dose

Population: Pharmacokinetic (PK) Population: Participants who received all RO5185426 doses without dose reduction up to and including Day 15 and provided at least PK assessments up to and including 8 to 10 hours after first dose on Day 15. Number of participants analyzed=participants evaluable for this outcome; n=participants evaluable for specified category.

Accumulation ratio is the ratio of AUC (0-8 hour) on Day 15 / AUC (0-8 hour) on Day 1.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=13 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg n=13 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
Mean RO5185426 Accumulation Ratios - Extension: BRAFV600E- Positive Melanoma and BRAFV600E- Positive CRC	11.61 ratio Standard Deviation 4.59	9.31 ratio Standard Deviation 3.90	—	—	—	—

PRIMARY outcome

Timeframe: Pre-morning dose, 0.5, 1, 2, 4, and 8 hour post-morning dose on Day 1, pre-morning dose on Day 2 and Day 8

Population: Pharmacokinetic (PK) Population: Participants who received all RO5185426 doses without dose reduction up to and including Day 15 and provided at least PK assessments up to and including 8 to 10 hours after first dose on Day 15. Number of participants analyzed=participants evaluable for this outcome; n=participants evaluable for specified category.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=3 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg n=6 Participants Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg n=5 Participants Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
Cmax of RO5185426 on Day 1 - Dose Escalation: MBP Formulation	1.14 micrograms per milliliter Standard Deviation 0.48	2.93 micrograms per milliliter Standard Deviation 0.39	2.72 micrograms per milliliter Standard Deviation 0.94	7.2 micrograms per milliliter Standard Deviation 6.06	7.12 micrograms per milliliter Standard Deviation 3.71	7.73 micrograms per milliliter Standard Deviation 3.54

PRIMARY outcome

Timeframe: Pre-morning dose, 0.5, 1, 2, 4, and 8 hour post-morning dose on Day 15, and pre-morning dose on Day 16

Population: Pharmacokinetic (PK) Population: Participants who received all RO5185426 doses without dose reduction up to and including Day 15 and provided at least PK assessments up to and including 8 to 10 hours after first dose on Day 15. Number of participants analyzed=participants evaluable for this outcome; n=participants evaluable for specified category.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg n=3 Participants Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg n=4 Participants Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
Cmax of RO5185426 on Day 15 - Dose Escalation: MBP Formulation	5.16 micrograms per milliliter Standard Deviation 2.72	11.64 micrograms per milliliter Standard Deviation 4.55	17.90 micrograms per milliliter Standard Deviation 8.01	31.15 micrograms per milliliter Standard Deviation 15.56	34.10 micrograms per milliliter Standard Deviation 5.47	84.30 micrograms per milliliter Standard Deviation 23.51

PRIMARY outcome

Timeframe: Pre-morning dose, 0.5, 1, 2, 4, and 8 hour post-morning dose on Day 1, pre-morning dose on Day 2 and Day 8

Population: Pharmacokinetic (PK) Population: Participants who received all RO5185426 doses without dose reduction up to and including Day 15 and provided at least PK assessments up to and including 8 to 10 hours after first dose on Day 15. Number of participants analyzed=participants evaluable for this outcome.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=3 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg n=6 Participants Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg n=5 Participants Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
Tmax of RO5185426 on Day 1 - Dose Escalation: MBP Formulation	2 hours Interval 2.0 to 4.0	3 hours Interval 1.0 to 4.0	3.21 hours Interval 2.0 to 4.08	6.29 hours Interval 3.92 to 8.0	3.29 hours Interval 2.03 to 8.02	4.33 hours Interval 2.0 to 8.0

PRIMARY outcome

Timeframe: Pre-morning dose, 0.5, 1, 2, 4, and 8 hour post-morning dose on Day 15, and pre-morning dose on Day 16

Population: Pharmacokinetic (PK) Population: Participants who received all RO5185426 doses without dose reduction up to and including Day 15 and provided at least PK assessments up to and including 8 to 10 hours after first dose on Day 15. Number of participants analyzed=participants evaluable for this outcome.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg n=3 Participants Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg n=4 Participants Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
Tmax of RO5185426 on Day 15 - Dose Escalation: MBP Formulation	1.5 hours Interval 0.0 to 4.05	2.0 hours Interval 0.0 to 8.0	4.10 hours Interval 2.5 to 8.45	4.07 hours Interval 0.0 to 24.0	4.33 hours Interval 1.0 to 8.0	0.41 hours Interval 0.0 to 2.33

PRIMARY outcome

Timeframe: Pre-morning dose and at 0.5, 1, 2, 4, and 8, and 24 hours post-morning dose

Population: Phamacokinetic (PK) Population: Participants who received all RO5185426 doses without dose reduction up to and including Day 15 and provided at least PK assessments up to and including 8 to 10 hours after first dose on Day 15. Number of participants analyzed=participants evaluable for this outcome; n=participants evaluable for specified category.

AUC (0-8 hour) was defined as the area under the plasma concentration-time curve from time equals zero (0) to 8 hours post-dose. AUC (0-24 hour) was defined as the area under the plasma concentration-time curve from time equals 0 to 24 hours post-dose. AUC (0-8 hour) and AUC (0-24 hour) were computed using the linear trapezoidal rule.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=29 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg n=21 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
AUC of RO5185426 on Day 1 - Extension: BRAFV600E- Positive Melanoma and BRAFV600E- Positive CRC AUC (0-8 hour) (n= 29, 21)	31.35 mcg*hr/mL Standard Deviation 15.51	31.53 mcg*hr/mL Standard Deviation 15.1	—	—	—	—
AUC of RO5185426 on Day 1 - Extension: BRAFV600E- Positive Melanoma and BRAFV600E- Positive CRC AUC (0-24 hour) (n= 5, 0)	108.52 mcg*hr/mL Standard Deviation 42.36	NA mcg*hr/mL Standard Deviation NA AUC (0-24) was optional in CRC group as steady state kinetics with respect to AUC (0-8) and AUC (0-24) were previously characterized.	—	—	—	—

PRIMARY outcome

Timeframe: Pre-morning dose and at 0.5, 1, 2, 4, and 8, and 24 hours post-morning dose

Population: Phamacokinetic (PK) Population: Participants who received all RO5185426 doses without dose reduction up to and including Day 15 and provided at least PK assessments up to and including 8 to 10 hours after first dose on Day 15. Number of participants analyzed=participants evaluable for this outcome; n=participants evaluable for specified category.

AUC (0-8 hour) was defined as the area under the plasma concentration-time curve from time equals 0 to 8 hours post-dose. AUC (0-24 hour) was defined as the area under the plasma concentration-time curve from time equals 0 to 24 hours post-dose. AUC (0-8 hour) and AUC (0-24 hour) were computed using the linear trapezoidal rule.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=14 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg n=13 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
AUC of RO5185426 on Day 15 - Extension: BRAFV600E- Positive Melanoma and BRAFV600E- Positive CRC AUC (0-8 hour) (n= 14, 13 )	289.26 ug*hr/mL Standard Deviation 105.88	262.42 ug*hr/mL Standard Deviation 101.37	—	—	—	—
AUC of RO5185426 on Day 15 - Extension: BRAFV600E- Positive Melanoma and BRAFV600E- Positive CRC AUC (0-24 hour) (n= 9, 11)	924.65 ug*hr/mL Standard Deviation 317.71	752.64 ug*hr/mL Standard Deviation 314.47	—	—	—	—

PRIMARY outcome

Timeframe: Pre-morning dose, 0.5, 1, 2, 4, and 8 hour post-morning dose on Day 1, pre-morning dose on Day 2 and Day 8

Population: Phamacokinetic (PK) Population: Participants who received all RO5185426 doses without dose reduction up to and including Day 15 and provided at least PK assessments up to and including 8 to 10 hours after first dose on Day 15. Number of participants analyzed=participants evaluable for this outcome.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=29 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg n=21 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
Cmax of RO5185426 on Day 1 - Extension: BRAFV600E- Positive Melanoma and BRAFV600E- Positive CRC	5.84 microgram/milliliter Standard Deviation 2.61	5.53 microgram/milliliter Standard Deviation 2.27	—	—	—	—

PRIMARY outcome

Timeframe: Pre-morning dose, 0.5, 1, 2, 4, and 8 hour post-morning dose on Day 15 and pre-morning dose on Day 16

Population: Phamacokinetic (PK) Population: Participants who received all RO5185426 doses without dose reduction up to and including Day 15 and provided at least PK assessments up to and including 8 to 10 hours after first dose on Day 15. Number of participants analyzed=participants evaluable for this outcome.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=14 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg n=13 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
Cmax of RO5185426 on Day 15 - Extension: BRAFV600E- Positive Melanoma and BRAFV600E- Positive CRC	44.31 microgram/milliliter Standard Deviation 16.38	38.55 microgram/milliliter Standard Deviation 15.92	—	—	—	—

PRIMARY outcome

Timeframe: Pre-morning dose, 0.5, 1, 2, 4, and 8 hour post-morning dose on Day 1, pre-morning dose on Day 2 and Day 8

Population: Phamacokinetic (PK) Population: Participants who received all RO5185426 doses without dose reduction up to and including Day 15 and provided at least PK assessments up to and including 8 to 10 hours after first dose on Day 15. Number of participants analyzed=participants evaluable for this outcome.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=29 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg n=21 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
Tmax of RO5185426 on Day 1 - Extension: BRAFV600E- Positive Melanoma and BRAFV600E- CRC	4 hours Interval 1.92 to 8.25	4 hours Interval 2.0 to 8.5	—	—	—	—

PRIMARY outcome

Timeframe: Pre-morning dose, 0.5, 1, 2, 4, and 8 hour post-morning dose on Day 15, and pre-morning dose on Day 16

Population: Phamacokinetic (PK) Population: Participants who received all RO5185426 doses without dose reduction up to and including Day 15 and provided at least PK assessments up to and including 8 to 10 hours after first dose on Day 15. Number of participants analyzed=participants evaluable for this outcome.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=14 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg n=13 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
Tmax of RO5185426 on Day 15 - Extension: BRAFV600E- Positive Melanoma and BRAFV600E- CRC	1.01 hours Interval 0.0 to 8.0	2.0 hours Interval 0.0 to 8.0	—	—	—	—

PRIMARY outcome

Timeframe: Screening, BL, until PD, or end of efficacy follow-up, up to data cutoff (up to 337 days)

Population: Modified ITT population: All participants with a measurable disease at BL and completed at least one post-baseline radiographic assessment or discontinued study medication early due to disease progression were considered evaluable for efficacy.

BOR of confirmed /unconfirmed (total) response was defined as CR or PR recorded from baseline until disease progression/recurrence according to Response Evaluation Criteria In Solid Tumors (RECIST) v 1.0 criteria. For target lesions (TLs), CR was defined as the disappearance of all TLs, and PR was defined as at least a 30 percent (%) decrease in the sum of longest diameters of the TLs, taking as a reference the baseline (BL) sum of longest diameters. For non-target lesions (NTLs), CR was defined as the disappearance of all NTLs and normalization of tumor marker levels. Confirmed responses were those which were confirmed by repeat assessments performed no less than four weeks after the criteria for response are first met. Percentage of participants with best overall response rate was calculated as the (number of participants with CR or PR) divided by (total number of participants in the cohort), and then multiplied by 100. The 95% Cl was determined using the Pearson-Clopper method.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=32 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
Percentage of Participants With a Confirmed and an Unconfirmed Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) According to RECIST Version (v) 1.0 - Extension: BRAFV600E- Positive Melanoma Confirmed BOR	56.3 percentage of participants Interval 37.7 to 73.6	—	—	—	—	—
Percentage of Participants With a Confirmed and an Unconfirmed Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) According to RECIST Version (v) 1.0 - Extension: BRAFV600E- Positive Melanoma Unconfirmed BOR	81.3 percentage of participants Interval 63.6 to 92.8	—	—	—	—	—

PRIMARY outcome

Timeframe: Screening, BL, until PD, or end of efficacy follow-up, up to data cutoff (up to 337 days)

Population: Modified ITT population: All participants with a measurable disease at BL and completed at least one post-baseline radiographic assessment or discontinued study medication early due to disease progression were considered evaluable for efficacy.

BOR of CR or PR was recorded from baseline until disease progression/recurrence according to RECIST v 1.0 criteria. For TLs, CR was defined as the disappearance of all TLs, and PR was defined as at least a 30% decrease in the sum of longest diameters of the TLs, taking as a reference the BL sum of longest diameters. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels. Confirmed responses were those which were confirmed by repeat assessments performed no less than four weeks after the criteria for response are first met Percentage of participants with best overall response rate was calculated as the (number of participants with CR or PR) divided by (total number of participants in the cohort), and then multiplied by 100. The 95% Cl was determined using the Pearson-Clopper method.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=20 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
Percentage of Participants With BOR of CR or PR According to RECIST v1.0 - Extension: BRAFV600E- Positive CRC	5.0 percentage of participants Interval 0.1 to 24.9	—	—	—	—	—

PRIMARY outcome

Timeframe: Screening, BL, until PD, or end of efficacy follow-up, up to data cutoff (up to 337 days)

Population: Modified ITT population: All participants with a measurable disease at BL and completed at least one post-baseline radiographic assessment or discontinued study medication early due to disease progression were considered evaluable for efficacy.

BOR of CR or PR was recorded from baseline until disease progression/recurrence according to RECIST v 1.0 criteria. For TLs, CR was defined as the disappearance of all TLs, and PR was defined as at least a 30% decrease in the sum of longest diameters of the TLs, taking as a reference the BL sum of longest diameters. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels. Percentage of participants with best overall response rate was calculated as the (number of participants with CR or PR) divided by (total number of participants in the cohort), and then multiplied by 100. The 95% Cl was determined using the Pearson-Clopper method.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=6 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg n=6 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg n=10 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
Percentage of Participants With BOR of CR or PR According to RECIST v1.0 - Dose Escalation: Original Formulation	0 percentage of participants Interval 0.0 to 0.0	0 percentage of participants Interval 0.0 to 0.0	10.0 percentage of participants Interval 0.3 to 44.5	0 percentage of participants Interval 0.0 to 0.0	—	—

PRIMARY outcome

Timeframe: Screening, BL, until PD, or end of efficacy follow-up, up to data cutoff (up to 337 days)

Population: Modified ITT population: All participants with a measurable disease at BL and completed at least one post-baseline radiographic assessment or discontinued study medication early due to disease progression were considered evaluable for efficacy.

BOR of CR or PR was recorded from baseline until disease progression/recurrence according to RECIST v 1.0 criteria. For TLs, CR was defined as the disappearance of all TLs, and PR was defined as at least a 30% decrease in the sum of longest diameters of the TLs, taking as a reference the BL sum of longest diameters. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels. Percentage of participants with best overall response rate was calculated as the (number of participants with CR or PR) divided by (total number of participants in the cohort), and then multiplied by 100. The 95% Cl was determined using the Pearson-Clopper method.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg n=4 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg n=3 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg n=5 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg n=7 Participants Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg n=6 Participants Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
Percentage of Participants With BOR of CR or PR According to RECIST v1.0 - Dose Escalation: MBP Formulation	0 percentage of participants Interval 0.0 to 0.0	25.0 percentage of participants Interval 0.6 to 80.6	33.3 percentage of participants Interval 0.8 to 90.6	40.0 percentage of participants Interval 5.3 to 85.3	28.6 percentage of participants Interval 3.7 to 71.0	50.0 percentage of participants Interval 11.8 to 88.2

SECONDARY outcome

Timeframe: Screening, BL, until PD, or end of efficacy follow-up, up to data cutoff (up to 337 days)

Population: Modified ITT population: Participants with confirmed CR or PR with a measurable disease at BL, and completed at least one post-baseline radiographic assessment or discontinued study medication early due to disease progression were considered. Seven participants were censored for analysis.

Duration of response for participants with confirmed CR or PR was the period of time measured between the date that the criteria for objective CR or PR (whichever status was recorded first) was met, and the first date that recurrent or PD was objectively documented (or death if before progression). PD was at least a 20% increase in the sum of longest diameters of TLs taking as reference the smallest sum of longest diameters recorded since the baseline measurements, or the appearance of one or more new lesion(s). In the event of no disease progression or documented death prior to study termination, analysis cutoff, or initiation of confounding anticancer therapy, duration of response was censored at the date of the last evaluable tumor assessment.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=18 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
Duration of CR or PR Using RECIST v 1.0 - Extension BRAFV600E- Positive Melanoma	227 days Interval 150.0 to The upper limit of the confidence interval was not estimable because of high number of censored participants.	—	—	—	—	—

SECONDARY outcome

Timeframe: Month 1, 3, 4, 6, 9, and Last event (350) days

Population: Modified ITT population: All participants with a measurable disease at BL and completed at least one post-baseline radiographic assessment or discontinued study medication early due to disease progression were considered. Eight participants were censored for analysis.

PFS was the period of time measured from the date of initiation of therapy to the date of the appearance of new metastatic lesions, objective tumor progression, or death if before progression. PD was defined according to the RECIST criteria (v 1.0) as increase by at least 20% in the sum of the longest diameters of each TL, taking as a reference the smallest sum of the longest diameters, reported since the start of treatment, or appearance of one or more new lesions. For Non-TLs, PD was defined as the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=32 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
Percentage of Participants With Progression-Free Survival (PFS) Using RECIST v 1.0 - Melanoma Extension Cohort Month 1	96.9 percentage of participants	—	—	—	—	—
Percentage of Participants With Progression-Free Survival (PFS) Using RECIST v 1.0 - Melanoma Extension Cohort Month 3	87.5 percentage of participants	—	—	—	—	—
Percentage of Participants With Progression-Free Survival (PFS) Using RECIST v 1.0 - Melanoma Extension Cohort Month 4	75.0 percentage of participants	—	—	—	—	—
Percentage of Participants With Progression-Free Survival (PFS) Using RECIST v 1.0 - Melanoma Extension Cohort Month 6	59.4 percentage of participants	—	—	—	—	—
Percentage of Participants With Progression-Free Survival (PFS) Using RECIST v 1.0 - Melanoma Extension Cohort Month 9	43.3 percentage of participants	—	—	—	—	—
Percentage of Participants With Progression-Free Survival (PFS) Using RECIST v 1.0 - Melanoma Extension Cohort 1 Year	16.9 percentage of participants	—	—	—	—	—
Percentage of Participants With Progression-Free Survival (PFS) Using RECIST v 1.0 - Melanoma Extension Cohort Last Event (350 Days)	16.9 percentage of participants	—	—	—	—	—

SECONDARY outcome

Timeframe: Screening, BL, until PD, or end of efficacy follow-up, up to data cutoff (up to 421 days)

Population: Modified ITT population: All participants with a measurable disease at BL and completed at least one post-baseline radiographic assessment or discontinued study medication early due to disease progression were considered. Eight participants were censored for analysis.

PFS was the period of time measured from the date of initiation of therapy to the date of the appearance of new metastatic lesions, objective tumor progression, or death if before progression. PD was at least a 20% increase in the sum of longest diameters of TLs taking as reference the smallest sum of longest diameters recorded since the baseline measurements, or the appearance of one or more new lesion(s). For Non-TLs, disease progression was defined as the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. In the event of no disease progression or documented death prior to study termination, analysis cutoff, or start of confounding anticancer therapy, PFS was censored at the date of the last evaluable tumor assessment.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=32 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
PFS Using RECIST v1.0 - Extension BRAFV600E Positive Melanoma	233 days Interval 149.0 to 297.0	—	—	—	—	—

SECONDARY outcome

Timeframe: Screening, BL, until PD, or end of efficacy follow-up, up to 444 days

Population: Modified ITT Population: All participants with a measurable disease at BL and completed at least one post-baseline radiographic assessment or discontinued study medication early due to disease progression were considered.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=32 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
Percentage of Participants Who Died - Extension: BRAFV600E- Positive Melanoma Month 4	6.2 percentage of participants	—	—	—	—	—
Percentage of Participants Who Died - Extension: BRAFV600E- Positive Melanoma Month 1	0 percentage of participants	—	—	—	—	—
Percentage of Participants Who Died - Extension: BRAFV600E- Positive Melanoma Month 3	3.1 percentage of participants	—	—	—	—	—
Percentage of Participants Who Died - Extension: BRAFV600E- Positive Melanoma Month 6	12.7 percentage of participants	—	—	—	—	—
Percentage of Participants Who Died - Extension: BRAFV600E- Positive Melanoma Month 9	29.4 percentage of participants	—	—	—	—	—
Percentage of Participants Who Died - Extension: BRAFV600E- Positive Melanoma Month 12	43.2 percentage of participants	—	—	—	—	—

SECONDARY outcome

Timeframe: Screening, BL, until PD, or end of efficacy follow-up, up to 444 days

Population: Modified ITT Population: All participants with a measurable disease at BL and completed at least one post-baseline radiographic assessment or discontinued study medication early due to disease progression were considered. Twenty participants were censored for analysis.

OS was the period of time measured from the date of initiation of therapy to the date of the death. In the event of no death prior to study termination or analysis data cutoff, OS was censored at the last known date that the patient was alive as documented on the follow-up case report form. If this date was not available, then the last known alive date from the database was used.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=32 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
Overall Survival (OS) - Extension: BRAFV600E- Positive Melanoma	NA days Interval 307.0 to The median OS was not reached as less than 50% participants had the event of interest.	—	—	—	—	—

SECONDARY outcome

Timeframe: Screening, BL, and up to 168 days

Population: Modified ITT population: Participants with a confirmed CR or PR with a measurable disease at BL and completed at least one post-baseline radiographic assessment or discontinued study medication early due to disease progression were considered.

Time to CR or PR was defined as the interval between the date of the first treatment to the date of the first documentation of confirmed CR or PR whichever occurred first, and not the date of confirmation at the subsequent tumor assessment. Time to response = Date of first response - initial dose date + 1.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=18 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
Time to CR or PR Using RECIST v1.0 - Extension: BRAFV600E- Positive Melanoma	56.5 days Interval 25.0 to 168.0	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-morning dose and at 0.5, 1, 2, 4, and 8, and 24 hours post-morning dose

Population: The analysis was planned only for those participants who received 80 or 120 mg dose of RO5185426 up to and including Day 15 and provided at least PK assessments up to and including 8 to 10 hours after first dose on Day 15. Number of participants analyzed=participants evaluable for this outcome; n=participants evaluable for specified category.

AUC (0-8 hour) was defined as the area under the plasma concentration-time curve from time equals 0 to 8 hours post-dose. AUC (0-24 hour) was defined as the area under the plasma concentration-time curve from time equals 0 to 24 hours post-dose. AUC (0-8 hour) and AUC (0-24 hour) were computed using the linear trapezoidal rule.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=10 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg n=19 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
Mean Dose-Normalized Steady-State AUC of RO5185426 80 mg and 120 mg Capsules - Dose Escalation: MBP Formulation and Extension: BRAFV600E- Positive Melanoma AUC (0-8hour) (n= 10, 19)	0.179 ug*hr/mL Standard Deviation 0.081	0.197 ug*hr/mL Standard Deviation 0.091	—	—	—	—
Mean Dose-Normalized Steady-State AUC of RO5185426 80 mg and 120 mg Capsules - Dose Escalation: MBP Formulation and Extension: BRAFV600E- Positive Melanoma AUC (0-24 hour) (n= 7, 9)	0.524 ug*hr/mL Standard Deviation 0.233	0.482 ug*hr/mL Standard Deviation 0.165	—	—	—	—

SECONDARY outcome

Timeframe: Pre-morning dose, 0.5, 1, 2, 4, and 8 hour post-morning dose on Day 1 and 15, pre-morning dose on Day 2 and Day 8, and Day 16

Population: PK Population: The analysis was planned only for those participants who received 80 or 120 mg dose of RO5185426 up to and including Day 15 and provided at least PK assessments up to and including 8 to 10 hours after first dose on Day 15. Number of participants analyzed=participants evaluable for this outcome.

Outcome measures

Measure	Dose Escalation: Original Formulation - 200 mg n=10 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg n=19 Participants Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 960 mg Participants received RO5185426 capsules in MBP formulation at a dose of 960 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.
Mean Dose-Normalized Steady-State Cmax of RO5185426 80 mg and 120 mg Capsules - Dose Escalation: MBP Formulation and Extension: BRAFV600E- Positive Melanoma	0.028 ug/mL Standard Deviation 0.012	0.030 ug/mL Standard Deviation 0.013	—	—	—	—

SECONDARY outcome

Timeframe: BL and Day 15

Tumor uptake of FDG was assessed by means of positron-emission tomography (PET)

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Pre-morning dose, 0.5, 1, 2, 4, and 8 hour post-morning dose on Day 1 and 15, pre-morning dose on Day 2, Day 8, and Day 16

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: BL and Day 15

The immunohisto-chemical analyses of the expression of phosphorylated ERK, cyclin D1, and Ki-67 in tumor-biopsy specimens was performed using hematoxylin and eosin staining.

Outcome measures

Outcome data not reported

Adverse Events

Dose Escalation: MBP Formulation - 160 mg

Serious events: 0 serious events

Other events: 4 other events

Deaths: 0 deaths

Dose Escalation: MBP Formulation - 240 mg

Serious events: 2 serious events

Other events: 4 other events

Deaths: 0 deaths

Dose Escalation: MBP Formulation - 320 mg

Serious events: 2 serious events

Other events: 3 other events

Deaths: 0 deaths

Dose Escalation: MBP Formulation - 360 mg

Serious events: 3 serious events

Other events: 5 other events

Deaths: 0 deaths

Dose Escalation: MBP Formulation - 720 mg

Serious events: 1 serious events

Other events: 7 other events

Deaths: 0 deaths

Dose Escalation: MBP Formulation - 1120 mg

Serious events: 2 serious events

Other events: 6 other events

Deaths: 0 deaths

Dose Escalation: Original Formulation - 200 mg

Serious events: 0 serious events

Other events: 6 other events

Deaths: 0 deaths

Dose Escalation: Original Formulation - 400 mg

Serious events: 0 serious events

Other events: 6 other events

Deaths: 0 deaths

Dose Escalation: Original Formulation - 800 mg

Serious events: 0 serious events

Other events: 10 other events

Deaths: 0 deaths

Dose Escalation: Original Formulation - 1600 mg

Serious events: 0 serious events

Other events: 4 other events

Deaths: 0 deaths

Extension: BRAFV600E-Positive Melanoma

Serious events: 18 serious events

Other events: 32 other events

Deaths: 0 deaths

Extension: BRAFV600E-Positive CRC

Serious events: 9 serious events

Other events: 21 other events

Deaths: 0 deaths

Serious adverse events

Measure	Dose Escalation: MBP Formulation - 160 mg n=4 participants at risk Participants received RO5185426 capsules in MBP formulation at a dose of 160 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 240 mg n=4 participants at risk Participants received RO5185426 capsules in MBP formulation at a dose of 240 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 320 mg n=3 participants at risk Participants received RO5185426 capsules in MBP formulation at a dose of 320 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 360 mg n=5 participants at risk Participants received RO5185426 capsules in MBP formulation at a dose of 360 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 720 mg n=7 participants at risk Participants received RO5185426 capsules in MBP formulation at a dose of 720 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg n=6 participants at risk Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 200 mg n=6 participants at risk Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg n=6 participants at risk Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg n=10 participants at risk Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg n=4 participants at risk Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Extension: BRAFV600E-Positive Melanoma n=32 participants at risk Participants with melanoma tumors that carried the V600E mutation of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) received RO5185246 capsules/tablets in MBP formulation at a dose of 960 mg bid until disease progression, death, or withdrawal from the study.	Extension: BRAFV600E-Positive CRC n=21 participants at risk Participants with CRC that carried the V600E mutation of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) received RO5185246 capsules/tablets in MBP formulation at a dose of 960 mg bid until disease progression, death, or withdrawal from the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma of skin	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	40.0% 2/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	31.2% 10/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	23.8% 5/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
General disorders Chest pain	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
General disorders Pyrexia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Blood and lymphatic system disorders Anaemia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Blood and lymphatic system disorders Leukopenia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Blood and lymphatic system disorders Neutropenia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Metabolism and nutrition disorders Dehydration	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	4.8% 1/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Psychiatric disorders Anxiety	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal cell carcinoma	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	3.1% 1/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant melanoma	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	3.1% 1/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Eye disorders Iridocyclitis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Eye disorders Uveitis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	3.1% 1/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Eye disorders Vitritis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	3.1% 1/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Alanine aminotransferase increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Aspartate aminotransferase increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Blood alkaline phosphatase increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Blood bilirubin increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	3.1% 1/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Blood amylase increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	4.8% 1/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Lipase increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	4.8% 1/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	3.1% 1/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	4.8% 1/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Psychiatric disorders Confusional state	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	4.8% 1/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Hepatobiliary disorders Cholangitis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	4.8% 1/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Diarrhoea	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	4.8% 1/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Pancreatitis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	3.1% 1/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	4.8% 1/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Hepatobiliary disorders Hepatotoxicity	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	4.8% 1/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Hepatobiliary disorders Hyperbilirubinaemia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	4.8% 1/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Cardiac disorders Atrial fibrillation	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	4.8% 1/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Vomiting	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	3.1% 1/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Abdominal pain	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	3.1% 1/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Blood and lymphatic system disorders White blood cell count increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	3.1% 1/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Palmar-plantar erythrodysaesthesia syndroma	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	3.1% 1/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Photosensitivity reaction	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	3.1% 1/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Rash	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	3.1% 1/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Rash papular	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	3.1% 1/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Cardiac disorders Pericardial effusion	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	3.1% 1/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Cardiac disorders Pericarditis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	3.1% 1/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Metabolism and nutrition disorders Hypertriglyceridaemia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	3.1% 1/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	3.1% 1/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
General disorders Asthenia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	3.1% 1/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Infections and infestations Abdominal abscess	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	3.1% 1/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Infections and infestations Lobar pneumonia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	3.1% 1/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Infections and infestations Staphylococcal infection	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	3.1% 1/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	3.1% 1/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Nervous system disorders Hemiparesis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	3.1% 1/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Surgical and medical procedures Tooth extraction	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	3.1% 1/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	3.1% 1/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.

Other adverse events

Measure	Dose Escalation: MBP Formulation - 160 mg n=4 participants at risk Participants received RO5185426 capsules in MBP formulation at a dose of 160 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 240 mg n=4 participants at risk Participants received RO5185426 capsules in MBP formulation at a dose of 240 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 320 mg n=3 participants at risk Participants received RO5185426 capsules in MBP formulation at a dose of 320 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 360 mg n=5 participants at risk Participants received RO5185426 capsules in MBP formulation at a dose of 360 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 720 mg n=7 participants at risk Participants received RO5185426 capsules in MBP formulation at a dose of 720 mg BID for 4 weeks.	Dose Escalation: MBP Formulation - 1120 mg n=6 participants at risk Participants received RO5185426 capsules in MBP formulation at a dose of 1120 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 200 mg n=6 participants at risk Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 200 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 400 mg n=6 participants at risk Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 400 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 800 mg n=10 participants at risk Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 800 mg BID for 4 weeks.	Dose Escalation: Original Formulation - 1600 mg n=4 participants at risk Participants received RO5185426 capsules in original (crystalline) formulation at a dose of 1600 mg BID for 4 weeks.	Extension: BRAFV600E-Positive Melanoma n=32 participants at risk Participants with melanoma tumors that carried the V600E mutation of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) received RO5185246 capsules/tablets in MBP formulation at a dose of 960 mg bid until disease progression, death, or withdrawal from the study.	Extension: BRAFV600E-Positive CRC n=21 participants at risk Participants with CRC that carried the V600E mutation of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) received RO5185246 capsules/tablets in MBP formulation at a dose of 960 mg bid until disease progression, death, or withdrawal from the study.
General disorders Pyrexia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	40.0% 2/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.6% 2/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.1% 9/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.6% 6/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
General disorders Asthenia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.4% 3/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
General disorders Fatigue	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	80.0% 4/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	42.9% 3/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	66.7% 4/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 3/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	60.0% 6/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	68.8% 22/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	57.1% 12/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
General disorders Oedema peripheral	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.4% 3/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Faecal incontinence	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Intestinal perforation	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
General disorders Pain	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	40.0% 2/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
General disorders Chest pain	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	15.6% 5/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
General disorders Face oedema	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
General disorders Fibrosis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
General disorders Malaise	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
General disorders Chills	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 3/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
General disorders Influenza like illness	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
General disorders Mucosal inflammation	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	12.5% 4/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Metabolism and nutrition disorders Hypercholesterolaemia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	40.0% 2/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	42.9% 3/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	18.8% 6/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Metabolism and nutrition disorders Hyperglycaemia	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	60.0% 3/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.6% 2/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	30.0% 3/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.1% 9/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	42.9% 9/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Metabolism and nutrition disorders Anorexia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 2/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Metabolism and nutrition disorders Hyperuricaemia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	40.0% 2/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	18.8% 6/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	19.0% 4/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Metabolism and nutrition disorders Hypoglycaemia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	40.0% 2/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	18.8% 6/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Metabolism and nutrition disorders Hypertriglyceridaemia	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	66.7% 2/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	18.8% 6/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Metabolism and nutrition disorders Hypomagnesaemia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	66.7% 2/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 2/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	21.9% 7/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.6% 6/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Metabolism and nutrition disorders Hypophosphataemia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	18.8% 6/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.5% 2/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Metabolism and nutrition disorders Decreased appetite	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 2/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	40.6% 13/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	23.8% 5/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Metabolism and nutrition disorders Dehydration	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.4% 3/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.4% 3/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Metabolism and nutrition disorders Hyperphosphataemia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	23.8% 5/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.1% 9/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	19.0% 4/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.4% 3/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.6% 6/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Metabolism and nutrition disorders Acidosis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Metabolism and nutrition disorders Hypernatraemia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Blood creatinine increased	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.6% 2/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 3/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 8/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	19.0% 4/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Blood alkaline phosphatase increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	42.9% 3/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	40.6% 13/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	23.8% 5/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Activated partial thromboplastin time prolonged	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.6% 2/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	40.0% 4/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	18.8% 6/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Alanine aminotransferase increased	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.6% 2/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	31.2% 10/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 3/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Aspartate aminotransferase increased	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	40.0% 2/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 8/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 3/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Weight decreased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.6% 2/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	21.9% 7/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.5% 2/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Blood uric acid increased	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 2/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Blood albumin decreased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.6% 2/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 2/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Blood bilirubin increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	15.6% 5/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Haemoglobin decreased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	40.0% 2/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 2/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	12.5% 4/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 3/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Platelet count increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.6% 2/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Blood albumin increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Blood chloride increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Blood glucose increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Blood iron decreased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Blood potassium decreased	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Blood triglycerides	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Blood triglycerides increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
General disorders Oedema	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.6% 2/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	12.5% 4/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
General disorders Xerosis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Metabolism and nutrition disorders Hypophagia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
General disorders Local Swelling	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Metabolism and nutrition disorders Fluid Retention	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations White blood cell count decreased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	15.6% 5/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Gamma-glutamyltransferase increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.4% 3/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Amylase increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Blood Phosphorus decreased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Blood Phosphorus increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Haematocrit decreased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Lipase increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Neutrophil count increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Blood Urea Increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.5% 2/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Protein Total Increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.5% 2/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Nausea	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	66.7% 2/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	60.0% 3/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.6% 2/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 3/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 2/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	43.8% 14/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 7/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Constipation	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	66.7% 2/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	60.0% 3/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.6% 2/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 2/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	21.9% 7/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	19.0% 4/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Diarrhoea	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	66.7% 2/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 3/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	34.4% 11/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	38.1% 8/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Vomiting	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.6% 2/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 3/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	37.5% 12/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 7/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Abdominal pain	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 3/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	12.5% 4/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 3/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Abdominal discomfort	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders faeces pale	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Flatulence	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.5% 2/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Abdominal pain upper	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.4% 3/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 3/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Anorectal discomfort	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Dry mouth	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Dyspepsia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Dysphagia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.4% 3/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Large intestine polyp	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Lip Swelling	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Eye disorders Photopsia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Peptic Ulcer	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Abdominal distension	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Gastritis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Hypoaesthesia oral	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Paraesthesia oral	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Tongue atrophy	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Crohn's disease	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Gastrointestinal disorders Stomatitis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations CSF pressure increase	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Carbon dioxide increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Cardiac murmur	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Electrocardiogram QT prolonged	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Low density lipoprotein increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Prothrombin time prolonged	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Prothombin time shortened	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Blood calcium decreased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 2/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Blood cholesterol increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Blood potassium increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Blood sodium decreased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Blood sodium increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Carbon dioxide decreased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations International normalised ratio increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Hypertriglyceridaemia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Rash	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	40.0% 2/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	71.4% 5/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	66.7% 4/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 2/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	53.1% 17/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 7/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Alopecia	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	40.0% 2/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	66.7% 4/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	56.2% 18/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	23.8% 5/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Photosensitivity reaction	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	60.0% 3/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.6% 2/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	43.8% 14/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 7/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Pruritus	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	75.0% 3/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	60.0% 3/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 2/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 8/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 3/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Dry Skin	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	66.7% 2/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	42.9% 3/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.1% 9/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	23.8% 5/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Skin Exfoliation	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	18.8% 6/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Erythema	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	12.5% 4/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Palmar-plantar erythrodysaesthesia syndrome	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 3/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	31.2% 10/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.5% 2/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Actinic keratosis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	15.6% 5/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Skin lesion	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	40.0% 2/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.4% 3/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.5% 2/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Hyperkeratosis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 8/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Keratosis pilaris	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	18.8% 6/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Rash papular	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Acne	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Campbell de Morgan spots	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Hair colour changes	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Nail bed disorder	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Night sweats	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.4% 3/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Psoriasis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Rash erythematous	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Rash pruritic	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Eye disorders Vitreous floaters	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Seborrhoeic dermatitis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders skin haemorrhage	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Skin mass	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.4% 3/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Solar lentigo	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Telangiectasia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Urticaria	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Rash maculo-papular	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.4% 3/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Dermatitis acneiform	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	12.5% 4/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Madarosis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	12.5% 4/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Dermal cyst	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.4% 3/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.5% 2/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Hyperhidrosis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.4% 3/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Papule	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.4% 3/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Blister	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Skin burning sensation	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.5% 2/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	60.0% 3/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	42.9% 3/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 3/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	68.8% 22/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	38.1% 8/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 3/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.1% 9/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	19.0% 4/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Musculoskeletal and connective tissue disorders Back pain	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	40.0% 2/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	18.8% 6/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.1% 9/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	19.0% 4/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Musculoskeletal and connective tissue disorders Muscle weakness	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.6% 2/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Skin and subcutaneous tissue disorders Musculoskeletal chest pain	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.4% 3/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Musculoskeletal and connective tissue disorders Arthritis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Musculoskeletal and connective tissue disorders Joint stiffness	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	12.5% 4/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Musculoskeletal and connective tissue disorders Musculoskeletal stiffness	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	12.5% 4/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Musculoskeletal and connective tissue disorders Pain in jaw	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Musculoskeletal and connective tissue disorders Joint range of motion decreased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Nervous system disorders Headache	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	40.0% 2/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.6% 2/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	37.5% 12/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.6% 6/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Nervous system disorders Dysgeusia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	12.5% 4/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.5% 2/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Nervous system disorders Dizziness	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.6% 2/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Nervous system disorders Neuropathy peripheral	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	15.6% 5/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Nervous system disorders Paraesthesia	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Nervous system disorders Peripheral sensory neuropathy	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	18.8% 6/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Nervous system disorders Memory impairment	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Nervous system disorders Amnesia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Nervous system disorders Dysaethesia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Nervous system disorders Hemianopia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Nervous system disorders Hypoaesthesia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.4% 3/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Nervous system disorders Lethargy	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Nervous system disorders Restless legs syndrome	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Nervous system disorders Somnolence	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Nervous system disorders Spinal cord compression	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Nervous system disorders Tremor	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Nervous system disorders Visual field defect	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Nervous system disorders Ataxia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Nervous system disorders Migraine	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Nervous system disorders Syncope	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Nervous system disorders Burning sensation	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Blood and lymphatic system disorders Anaemia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	100.0% 3/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	40.0% 2/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	42.9% 3/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.1% 9/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	19.0% 4/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Blood and lymphatic system disorders Lymphopenia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	60.0% 3/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	21.9% 7/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.6% 6/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Blood and lymphatic system disorders Leukopenia	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	40.0% 2/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	12.5% 4/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Blood and lymphatic system disorders Neutropenia	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Blood and lymphatic system disorders Microcytic anaemia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Blood and lymphatic system disorders Thrombocytosis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Blood and lymphatic system disorders Lymphadenopathy	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	75.0% 3/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	40.0% 2/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	31.2% 10/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Respiratory, thoracic and mediastinal disorders Dysphonia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	40.0% 2/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Respiratory, thoracic and mediastinal disorders Dyspnoea	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.4% 3/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.6% 2/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.5% 2/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Respiratory, thoracic and mediastinal disorders Rhinitis allergic	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	12.5% 4/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.6% 2/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Respiratory, thoracic and mediastinal disorders Upper-airway cough syndrome	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Respiratory, thoracic and mediastinal disorders Allergic pharyngitis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Respiratory, thoracic and mediastinal disorders Pulmonary congestion	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Respiratory, thoracic and mediastinal disorders Sinus congestion	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Respiratory, thoracic and mediastinal disorders Allergic sinusitis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Respiratory, thoracic and mediastinal disorders Pleuritic pain	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Respiratory, thoracic and mediastinal disorders Sinus disorder	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.4% 3/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 3/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Eye disorders Dry eye	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.4% 3/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Eye disorders Photophobia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	15.6% 5/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Eye disorders Uveitis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.4% 3/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Eye disorders Visual impairment	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Eye disorders Altered visual depth perception	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Eye disorders Conjunctival irritation	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Eye disorders Eye discharge	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Eye disorders Lacrimation increased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Eye disorders Ocular hyperaemia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Eye disorders Vision blurred	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	12.5% 4/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Eye disorders Eye irritation	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Eye disorders Iridocyclitis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Infections and infestations Urinary tract infection	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	19.0% 4/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Infections and infestations Upper respiratory tract infection	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.6% 2/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	15.6% 5/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Infections and infestations Bronchitis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Infections and infestations Candida infection	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Infections and infestations cystitis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Infections and infestations Folliculitis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Infections and infestations Gingivitis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Infections and infestations Impetigo	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Infections and infestations Nasopharyngitis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Infections and infestations Oral herpes	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Infections and infestations Rhinitis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Infections and infestations Sinusitis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Infections and infestations Vaginal infection	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Infections and infestations Viral infection	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Infections and infestations Cellulitis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Infections and infestations Device related infection	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Infections and infestations Diverticulitis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Infections and infestations Laryngitis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Infections and infestations Peritonitis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Infections and infestations Pneumonia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Infections and infestations Conjunctivitis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	18.8% 6/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Infections and infestations oral candidiasis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.4% 3/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Psychiatric disorders Insomnia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	12.5% 4/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.5% 2/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Psychiatric disorders Anxiety	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Psychiatric disorders Confusional state	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Psychiatric disorders Mood altered	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Psychiatric disorders Depression	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	12.5% 4/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Psychiatric disorders Irritability	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Psychiatric disorders Mental status change	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Psychiatric disorders Sleep disorder	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Skin papilloma	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 3/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 8/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Seborrhoeic keratosis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.5% 2/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Acrochordon	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.4% 3/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Keratoacanthoma	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Melanocytic naevus	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.4% 3/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Oral papilloma	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumor pain	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to central nervous system	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal cell carcinoma	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Fibrous histiocytoma	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Injury, poisoning and procedural complications Sunburn	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	31.2% 10/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.5% 2/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Injury, poisoning and procedural complications Arthropod bite	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.5% 2/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Injury, poisoning and procedural complications Contusion	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Injury, poisoning and procedural complications Excoriation	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Injury, poisoning and procedural complications Laceration	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Injury, poisoning and procedural complications post procedural discharge	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Injury, poisoning and procedural complications Procedural pain	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Injury, poisoning and procedural complications Radiation skin injury	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Injury, poisoning and procedural complications Wound	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Injury, poisoning and procedural complications Post procedural complication	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Injury, poisoning and procedural complications Post procedural inflammation	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Injury, poisoning and procedural complications Spinal fracture	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Injury, poisoning and procedural complications Wound complication	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Renal and urinary disorders Proteinuria	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	50.0% 2/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	31.2% 10/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.6% 6/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Renal and urinary disorders Haemoglobinuria	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Renal and urinary disorders Micturition urgency	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Renal and urinary disorders Pollakiuria	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Renal and urinary disorders Bladder discomfort	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Renal and urinary disorders Dysuria	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.5% 2/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Renal and urinary disorders Urinary incontinence	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Renal and urinary disorders Urinary retention	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Renal and urinary disorders Ketonuria	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Renal and urinary disorders haematuria	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.5% 2/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Vascular disorders Flushing	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	12.5% 4/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Vascular disorders Lymphoedema	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Vascular disorders Hot Flush	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Vascular disorders Vasculitis	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Vascular disorders Hypotension	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	9.5% 2/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Vascular disorders Hypertension	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Reproductive system and breast disorders Menopausal symptoms	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 2/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Reproductive system and breast disorders Erectile dysfunction	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Reproductive system and breast disorders Deyronie's disease	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Reproductive system and breast disorders Vaginal lesion	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Reproductive system and breast disorders Pelvic pain	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Reproductive system and breast disorders Breast pain	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Reproductive system and breast disorders Nipple disorder	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	6.2% 2/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Cardiac disorders Atrial flutter	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Cardiac disorders Pericardial effusion	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Cardiac disorders Sinus bradycardia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Cardiac disorders Trachycardia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Cardiac disorders Ventricular tachycardia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Hepatobiliary disorders Hyperbilirubinaemia	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	14.3% 1/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	12.5% 4/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	28.6% 6/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Ear and labyrinth disorders Ear congestion	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Ear and labyrinth disorders Ear pain	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Ear and labyrinth disorders Vertigo	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	25.0% 1/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Endocrine disorders Inappropriate antidiuretic hormone secretion	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	33.3% 1/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Immune system disorders Allergy to arthropod sting	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	20.0% 1/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.
Investigations Platelet count decreased	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/3 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/5 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/7 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	16.7% 1/6 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	10.0% 1/10 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/4 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/32 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.	0.00% 0/21 For MBP Formulation, one patient not dosed, so only 29 patients are evaluable for safety measures although at the beginning of the study 30 patients started.

Additional Information

Dr. Henry Hsu

Plexxikon Inc.

Phone: 510-647-4000

Email: hhsu@plexxikon.com

Results disclosure agreements

• Principal investigator is a sponsor employee The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
• Publication restrictions are in place

Restriction type: OTHER